FORT COLLINS, CO — March 29 — The first Phase III study of Atrisone (dapsone topical gel; Atrix Laboratories, Inc.) for the treatment of acne found the drug to be statistically superior to vehicle on all four primary efficacy end points and both secondary efficacy end points.
"Based on the results of this initial Phase III study, Atrisone appears to be safe and clinically effective for the management of acne," said Dr. Stephen Warren, Atrix's vice president of research and development. "We have surpassed our study objectives by achieving superiority on all six endpoints."
"Of particular significance, he said, "the product appeared to be effective at reducing inflammatory lesions, often associated with the more severe cases of acne. We now plan to move forward with the second Phase III clinical trial."